HITI Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of 0.56% compared to High Tide, Inc.'s net margin of 42.95%. High Tide, Inc.'s return on equity of -6.56% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

High Tide, Inc. has a consensus price target of $6.00, signalling upside risk potential of 116.61%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 3.01%. Given that High Tide, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe High Tide, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

High Tide, Inc. has a beta of 0.460, which suggesting that the stock is 54.014% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

High Tide, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. High Tide, Inc. pays 5.25% of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. High Tide, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

High Tide, Inc. quarterly revenues are $108.9M, which are larger than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. High Tide, Inc.'s net income of $605.5K is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, High Tide, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for High Tide, Inc. is 0.56x versus 8.59x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Health Advance, Inc. has a net margin of 0.56% compared to High Tide, Inc.'s net margin of --. High Tide, Inc.'s return on equity of -6.56% beat Health Advance, Inc.'s return on equity of --.

High Tide, Inc. has a consensus price target of $6.00, signalling upside risk potential of 116.61%. On the other hand Health Advance, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that High Tide, Inc. has higher upside potential than Health Advance, Inc., analysts believe High Tide, Inc. is more attractive than Health Advance, Inc..

High Tide, Inc. has a beta of 0.460, which suggesting that the stock is 54.014% less volatile than S&P 500. In comparison Health Advance, Inc. has a beta of 0.730, suggesting its less volatile than the S&P 500 by 26.98%.

High Tide, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Advance, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. High Tide, Inc. pays 5.25% of its earnings as a dividend. Health Advance, Inc. pays out -- of its earnings as a dividend. High Tide, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

High Tide, Inc. quarterly revenues are $108.9M, which are larger than Health Advance, Inc. quarterly revenues of --. High Tide, Inc.'s net income of $605.5K is higher than Health Advance, Inc.'s net income of --. Notably, High Tide, Inc.'s price-to-earnings ratio is -- while Health Advance, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for High Tide, Inc. is 0.56x versus -- for Health Advance, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of 0.56% compared to High Tide, Inc.'s net margin of --. High Tide, Inc.'s return on equity of -6.56% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

High Tide, Inc. has a consensus price target of $6.00, signalling upside risk potential of 116.61%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 449.6%. Given that Oncolytics Biotech, Inc. has higher upside potential than High Tide, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than High Tide, Inc..

High Tide, Inc. has a beta of 0.460, which suggesting that the stock is 54.014% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

High Tide, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. High Tide, Inc. pays 5.25% of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend. High Tide, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

High Tide, Inc. quarterly revenues are $108.9M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. High Tide, Inc.'s net income of $605.5K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, High Tide, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for High Tide, Inc. is 0.56x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands, Inc. has a net margin of 0.56% compared to High Tide, Inc.'s net margin of 0.72%. High Tide, Inc.'s return on equity of -6.56% beat Tilray Brands, Inc.'s return on equity of -84.8%.

High Tide, Inc. has a consensus price target of $6.00, signalling upside risk potential of 116.61%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $16.17 which suggests that it could grow by 44.86%. Given that High Tide, Inc. has higher upside potential than Tilray Brands, Inc., analysts believe High Tide, Inc. is more attractive than Tilray Brands, Inc..

High Tide, Inc. has a beta of 0.460, which suggesting that the stock is 54.014% less volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.794%.

High Tide, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. High Tide, Inc. pays 5.25% of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend. High Tide, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

High Tide, Inc. quarterly revenues are $108.9M, which are smaller than Tilray Brands, Inc. quarterly revenues of $209.5M. High Tide, Inc.'s net income of $605.5K is lower than Tilray Brands, Inc.'s net income of $1.5M. Notably, High Tide, Inc.'s price-to-earnings ratio is -- while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for High Tide, Inc. is 0.56x versus 3.89x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.